Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

The first dominant SARS‐CoV‐2 Omicron variant BA. 1 harbours 35 mutations in its Spike
protein from the original SARS‐CoV‐2 variant that emerged late 2019. Soon after its …

Continuous evolution of Omicron has led to a rapid and simultaneous emergence of
numerous variants that display growth advantages over BA. 5 (ref.). Despite their divergent …

The Omicron lineage of SARS-CoV-2, which was first described in November 2021, spread
rapidly to become globally dominant and has split into a number of sublineages. BA. 1 …

Recently, the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Omicron
variant (B. 1.1. 529) was first identified in Botswana in November 2021. It was first reported …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged
pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus …

On 24 th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B. 1.1.
529 was announced, containing far more mutations in Spike (S) than previously reported …

Abstract The Omicron (B. 1.1. 529) variant of severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) was initially identified in November 2021 in South Africa and Botswana, as …

The unprecedented public health and economic impact of the COVID-19 pandemic caused
by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been …

The past several months have witnessed the emergence of SARS-CoV-2 variants with novel
spike protein mutations that are influencing the epidemiological and clinical aspects of the …